Literature DB >> 12818287

Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites.

Hwan Y Yoo1, David Edwin, Paul J Thuluvath.   

Abstract

OBJECTIVE: It has recently been suggested that the Model for End-Stage Liver Disease (MELD) is a better and a more objective predictor of mortality in patients with end-stage liver disease. The aim of our study was to determine the relationship of the MELD score to hepatic encephalopathy (HE), as determined by electroencephalography (EEG) and clinical and neuropsychometric examination, and ascites.
METHODS: A total of 66 patients underwent EEG, a neuropsychometric screening by Mini-Mental State Examination, Trails Making Tests, Rey-Osterreith Complex Figure, and Hopkins Verbal Learning Tests, and a clinical assessment for HE. The MELD score was calculated as previously described by using serum creatinine, bilirubin, and international normalized ratio. Subclinical HE was diagnosed if clinical examination did not detect HE but neuropsychometric tests and EEG were abnormal.
RESULTS: Sixteen patients had no HE, 28 had subclinical HE, and 22 had clinical HE. Age, sex, race, and cause of liver disease were similar in all three groups. Child-Turcotte-Pugh score was significantly higher in patients with clinical HE compared with the other two groups. There was only a modest correlation (r = 0.5) between Child-Turcotte-Pugh and the MELD scores. The distribution and mean MELD scores were similar in patients with or without HE as determined by clinical or neuropsychometric examination and EEG. Approximately 90% of patients with clinical HE or abnormal EEG and neuropsychometric tests had a MELD score less than 25. Similarly, the MELD score was not affected by the severity of ascites.
CONCLUSION: The MELD score does not correlate well with severity of HE or ascites. Patients with HE and ascites might not receive liver transplantation in a timely manner if MELD scores were to be used exclusively for organ allocation.

Entities:  

Mesh:

Year:  2003        PMID: 12818287     DOI: 10.1111/j.1572-0241.2003.07466.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

Review 1.  Post-hepatectomy liver failure.

Authors:  Rondi Kauffmann; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  MELD score does not discriminate against patients with hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Kia Saeian
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

3.  Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis.

Authors:  Patrick G Northup; Ryan C Wanamaker; Vanessa D Lee; Reid B Adams; Carl L Berg
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Prediction of Post-operative Mortality in Patients with HCV-related Cirrhosis Undergoing Non-Hepatic Surgeries.

Authors:  Khalid Hemida; Reham Ezzat Al Swaff; Sherif Sadek Shabana; Hani Said; Fatma Ali-Eldin
Journal:  J Clin Diagn Res       Date:  2016-10-01

5.  Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.

Authors:  Gregory T Everson; Mitchell L Shiffman; John C Hoefs; Timothy R Morgan; Richard K Sterling; David A Wagner; Shannon Lauriski; Teresa M Curto; Anne Stoddard; Elizabeth C Wright
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

6.  MELD-based indices as predictors of mortality in chronic liver disease patients who undergo emergency surgery with general anesthesia.

Authors:  Sung Hoon Kim; Yoon Dae Han; Jae Gil Lee; Do Young Kim; Sae Byeol Choi; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2011-09-13       Impact factor: 3.452

7.  Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.

Authors:  K Atiemo; A Skaro; H Maddur; L Zhao; S Montag; L VanWagner; S Goel; A Kho; B Ho; R Kang; J L Holl; M M Abecassis; J Levitsky; D P Ladner
Journal:  Am J Transplant       Date:  2017-04-04       Impact factor: 8.086

8.  Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Authors:  Marc G Ghany; Anna S F Lok; James E Everhart; Gregory T Everson; William M Lee; Teresa M Curto; Elizabeth C Wright; Anne M Stoddard; Richard K Sterling; Adrian M Di Bisceglie; Herbert L Bonkovsky; Chihiro Morishima; Timothy R Morgan; Jules L Dienstag
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

9.  Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China.

Authors:  Yu-Yuan Li; Yu-Qiang Nie; Wei-Hong Sha; Zheng Zeng; Fu-Ying Yang; Li Ping; Lin Jia
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

10.  Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.

Authors:  Chiranjeevi Gadiparthi; George Cholankeril; Eric R Yoo; Menghan Hu; Robert J Wong; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2018-04-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.